Hypertensive emergency targets and drugs
The ESC 2024 hypertensive emergency table beside the ACC/AHA compelling conditions: aortic dissection (SBP < 120 and HR < 60 immediately, β-blocker before any vasodilator), acute coronary syndrome and acute cardiogenic pulmonary oedema (SBP < 140, nitroglycerin or labetalol; nitroprusside or nitroglycerin with a loop diuretic), malignant hypertension with or without TMA or AKI (MAP −20–25% over hours), hypertensive encephalopathy (MAP −20–25% immediately), phaeochromocytoma and cocaine or sympathomimetic crisis (phentolamine, benzodiazepines, no unopposed β-blockade) and severe pre-eclampsia, eclampsia or HELLP (treat at ≥ 160/110, target < 160/105, labetalol, nicardipine or hydralazine with magnesium sulphate), with ACOG, ISSHP and NICE obstetric recommendations. The entered BP and heart rate are turned into numeric targets, and a medication check strikes out drugs ruled out by home medications (enalaprilat on sacubitril/valsartan; nitroglycerin and nitroprusside after a PDE5 inhibitor).
- IV opioid analgesia (pain drives catecholamines)
- β-blocker intolerance: IV diltiazem or verapamil for rate control
- Immediate surgical referral for type A
- Any vasodilator before the heart rate is controlled (reflex tachycardia raises aortic wall stress)
- Hydralazine
- Immediately: SBP < 120 mmHg and HR < 60 bpmESC 2024Esmolol with nitroprusside, nitroglycerin or nicardipine; alternatives labetalol or metoprolol.
- IV β-blocker titrated to HR ≤ 60 bpm and SBP 100–120 mmHgIESC 2024 aortaWith analgesia; add a vasodilator once rate is controlled.
- Aortic dissection: SBP < 120 mmHg during the first hourIACC/AHA 2017
- IV β-blocker to HR < 60 bpm and SBP < 120 mmHgIACC/AHA 2022 aorta
- β-blocker contraindicated: non-dihydropyridine calcium-channel blocker for rate controlACC/AHA 2022 aorta
- Do not start a vasodilator before rate controlACC/AHA 2022 aorta
| Condition | Timeframe | Target | First line | Alternatives |
|---|---|---|---|---|
| Acute aortic dissection | Immediately (ESC); within the first hour (ACC/AHA), usually within 20 min | SBP < 120 mmHg and HR < 60 bpm | Esmolol, Labetalol | Sodium nitroprusside, Nicardipine, Clevidipine, Nitroglycerin |
| Acute coronary syndrome | Immediately | SBP < 140 mmHg | Nitroglycerin, Labetalol | Urapidil, Esmolol, Clevidipine, Nicardipine |
| Acute cardiogenic pulmonary oedema | Immediately | SBP < 140 mmHg | Sodium nitroprusside, Nitroglycerin | Urapidil, Clevidipine, Enalaprilat |
| Malignant hypertension ± TMA or AKI | Over several hours | Lower MAP by 20–25% | Labetalol, Nicardipine | Sodium nitroprusside, Urapidil, Clevidipine |
| Hypertensive encephalopathy | Immediately | Lower MAP by 20–25% | Labetalol, Nicardipine | Sodium nitroprusside, Clevidipine, Urapidil |
| Phaeochromocytoma or cocaine / sympathomimetic crisis | Immediately; SBP < 140 within the first hour (ACC/AHA) | SBP < 140 mmHg (ACC/AHA); no fixed ESC target | Phentolamine | Sodium nitroprusside, Urapidil, Clevidipine, Nicardipine |
| Severe pre-eclampsia, eclampsia or HELLP | Within 30–60 min of confirmed severe BP | Treat at ≥ 160/110; target < 160/105 (ESC), 140–150/90–100 (ACOG) | Labetalol, Nicardipine, Hydralazine | — |
- McEvoy JW, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024;45:3912-4018.
- van den Born BJH, Lip GYH, et al. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother 2019;5:37-46.
- Whelton PK, Carey RM, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension 2018;71:e13-e115.
- Mazzolai L, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J 2024;45:3538-3700.
- Isselbacher EM, et al. 2022 ACC/AHA Guideline for the diagnosis and management of aortic disease. Circulation 2022;146:e334-e482.
- American College of Obstetricians and Gynecologists. Gestational hypertension and preeclampsia: ACOG Practice Bulletin No. 222. Obstet Gynecol 2020;135:e237-e260.
- American College of Obstetricians and Gynecologists. Clinical management guidelines: Emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. ACOG Committee Opinion No. 767. Obstet Gynecol 2019;133:e174-e180.
- Magee LA, Brown MA, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens 2022;27:148-169.
- National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. NICE guideline NG133, 2019 (updated 2023).
- Regitz-Zagrosek V, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018;39:3165-3241.
- Amsterdam EA, et al. 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes. Circulation 2014;130:e344-e426.
- McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-3726.
- Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure. Circulation 2022;145:e895-e1032 (ARNI: no ACE inhibitor within 36 h).
- Byrne RA, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44:3720-3826.